

Evaluating Efficacy and Safety of Tofersen in Adults with *SOD1*-ALS: Results from the Phase 3 VALOR Trial and Open-Label Extension

Miller TM,¹ Cudkowicz ME,² Genge A,³ Shaw PJ,⁴ Sobue G,⁵ Cochrane T,⁶ Nestorov I,⁶ Graham D,⁶ Sun P,⁶ McNeill M,⁷ Fanning L,⁶ Ferguson TA,⁶ Fradette S,⁶ on behalf of The VALOR and OLE Working Group

¹Washington University School of Medicine, St. Louis, MO, USA; ²Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ³Montreal Neurological Institute and Hospital, Montreal, QC, Canada; ⁴Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; ⁵Aichi Medical University, Aichi, Japan; ⁶Biogen, Cambridge, MA, USA; ⁷Biogen, Maidenhead, UK



Presentation 48



Plain language
summary

ENCALS (2022) European Network for the Cure of Amyotrophic Lateral Sclerosis - 20th Meeting | 1-3 June 2022

Disclosures

- TMM: advisory board and clinical research support for Biogen; licensing agreement with, and consulting for, Ionis Pharmaceuticals, Inc.; consultant for Cytokinetics; licensing agreements with C2N; advisory board for Disarm Therapeutics; and advisory board for UCB Pharma
- MEC: compensation from an advisory board for Biogen; compensation from QurAlis, RRD, Sunovian, Cytokinetics, Takeda, Regeneron, Transposon, and Locust Walk; member of Praxis Board of Directors
- AG: ad hoc consultant for genetic testing for Biogen; consultant on ALS trial design for Alexion, AL-S Pharma, Calico, Cytokinetics, and Sanofi; and CMO at QurAlis
- PJS: advisory board member for Biogen, Aclipse Therapeutics, Quell Therapeutics, BenevolentAI, and QurAlis and receives research support from Quell Therapeutics, Aclipse Therapeutics, Pfizer, and SwanBio. Support for clinical trials participation has been received from Biogen, Alexion, the EU Horizon programme and UK NIHR.
- GS: compensation from Mitsubishi Tanabe Pharma, Takeda, and Sumitomo Dainippon Pharma
- TC, IN, DG, PS, MM, LF, TAF, and SF: employees of and hold stock/stock options in Biogen

This study was sponsored by Biogen (Cambridge, MA, USA). Writing and editorial support was provided by Excel Scientific Solutions (Fairfield, CT, USA): funding was provided by Biogen. Tofersen was discovered by Ionis Pharmaceuticals, Inc.



Tofersen is an investigational antisense oligonucleotide (ASO) designed to reduce synthesis of SOD1 protein through degradation of *SOD1* mRNA^{1,2}

VALOR and its Open-Label Extension

VALOR¹
28 weeks
Tofersen 100 mg vs. placebo

Data were integrated to evaluate early- vs. delayed-start tofersen initiation

OLE²
~3–7 years
Tofersen 100 mg


Data presented October 2021³

- Data cut date: July 2021
 - VALOR completion + first interim of the OLE
 - All participants had the opportunity for at least **6 months** of follow-up
- **Prespecified subgroups** based on:
 - Mutation/ALSFRS-R slope OR
 - Baseline neurofilament

Data in this presentation


- Data cut date: January 2022
 - New interim cut of the OLE
 - All participants had the opportunity for at least **12 months** of follow-up
- Prior to database lock, baseline plasma NfL was incorporated as a covariate, thus **controlling for heterogeneity of disease progression in the overall (ITT) population**

Participant Disposition



Target Engagement

Adjusted geometric mean ratio (95% CI) to baseline of total CSF SOD1 protein



Week 52 percent reduction (GMR) from baseline:
21% (95% CI, 4–35%)
33% (95% CI, 21–42%)


○ Placebo → Delayed-start tofersen, n =	36	36	30	27	25
● Early-start tofersen, n =	71	64	57	52	53

CSF = cerebrospinal fluid; OLE = open-label extension; SOD1 = superoxide dismutase 1

Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data; based on natural log transformed data. The model includes covariates for the corresponding baseline value i.e. log value, and use of riluzole or edaravone.

Effect on Neurofilament

Adjusted geometric mean ratio (95% CI) to baseline of plasma NfL



Week 52 percent reduction (GMR) from baseline:
41% (95% CI, 26–54%)
51% (95% CI, 42–60%)


○ Placebo → Delayed-start tofersen, n =	36	35	31	28	23
● Early-start tofersen, n =	71	62	53	50	50

NfL = neurofilament light chain; OLE = open-label extension

Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data; based on natural log transformed data. The model includes covariates for the corresponding baseline value i.e. log value, and use of riluzole or edaravone.

Effect on Clinical Function

Adjusted mean (\pm SE) change from baseline in ALSFRS-R total score




○ Placebo → <u>Delayed-start tofersen</u> , n =	36	36	33	29	28
● <u>Early-start tofersen</u> , n =	72	66	63	58	57

ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale–Revised; OLE = open-label extension
 Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data. The model includes covariates for the corresponding baseline value, baseline plasma NfL, and use of riluzole or edaravone.

Effect on Respiratory Function

Adjusted mean (\pm SE) change from baseline in percent-predicted SVC




○ <u>Placebo</u> → <u>Delayed-start tofersen</u> , n =	36	34	25	20	20
● <u>Early-start tofersen</u> , n =	72	59	52	39	38

OLE = open-label extension; SVC = slow vital capacity

Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data. The model includes covariates for the corresponding baseline value, baseline plasma NfL, and use of riluzole or edaravone.

Effect on Muscle Strength

Adjusted mean (\pm SE) change from baseline in HHD megascore




○ <u>Placebo</u> → <u>Delayed-start tofersen</u> , n =	36	35	27	24	25
● <u>Early-start tofersen</u> , n =	72	64	58	47	42

HHD = handheld dynamometry; OLE = open-label extension

Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data. The model includes covariates for the corresponding baseline value, baseline plasma NfL, and use of riluzole or edaravone.

Time-to-Event Analyses

Kaplan-Meier plot of time to death or PV



Placebo →
Delayed-start
tofersen, n =

Early-start
tofersen, n =

Events	Early-start tofersen	Placebo → delayed-start tofersen	Hazard ratio
Death or Permanent Ventilation	12/72 (16.7%)	8/36 (22.2%)	0.36 95% CI, 0.137–0.941
Death	8/72 (11.1%)	6/36 (16.7%)	0.27 95% CI, 0.084–0.890
Death with additional post-withdrawal vital status data	12/72 (16.7%)	11/36 (30.6%)	0.24 95% CI: 0.096, 0.602
Death, PV, or withdrawal due to disease progression	18/72 (25.0%)	13/36 (36.1%)	0.38 95% CI: 0.180, 0.821

Median time to death and time to death or PV were non-estimable due to the number of events


OLE = open-label extension; PV = permanent ventilation

Time to death or permanent ventilation is defined as the time from first dose to death or PV (≥22 hours of mechanical ventilation per day for ≥21 consecutive days), whichever comes first. Participants who do not meet the endpoint definition are censored a participant's last known alive date. Events are based on adjudicated events by an independent committee. Plots are Kaplan-Meier curves. Hazard ratios and confidence intervals are based on a Cox regression model adjusted for baseline plasma NFL, and riluzole or edaravone use.


Effect on ALS PROs

Adjusted mean (\pm SE) change from baseline


ALSAQ-5 (0 to 100 points)



EQ-5D-5L utility score (-0.594 to 1.0^a)



FSS (9 to 63 score)



○ Placebo → Delayed-start tofersen, n =

● Early-start tofersen, n =

	36	36	31	28	26
Early-start tofersen, n =	72	66	61	50	49

Adjusted mean difference, Week 52:
-10.3
 (95% CI: -17.3 to -3.2), p=0.0044

	36	35	31	28	26
Early-start tofersen, n =	72	65	61	49	47

Adjusted mean difference, Week 52:
0.2
 (95% CI: 0.13 to 0.32), p<0.0001

	36	35	31	28	26
Early-start tofersen, n =	72	66	61	50	49

Adjusted mean difference, Week 52:
-3.8
 (95% CI: -9.0 to 1.38), p=0.1493

ALS = amyotrophic lateral sclerosis; ALSAQ-5 = 5 Item ALS Assessment Questionnaire; EQ-5D = EuroQOL-5 Dimension 5-Level Questionnaire; FSS = Fatigue Severity Scale; OLE = open-label extension; PRO = patient-reported outcome

Analysis is based on ANCOVA model in conjunction with multiple imputation for missing data. The model includes covariates for the corresponding baseline value, baseline plasma NfL, and use of riluzole or edaravone.

^aUsing UK valuation weights.


Summary of Adverse Events

	VALOR		VALOR and OLE Integrated ^d
	Placebo (N = 36) n (%)	Tofersen 100 mg (N = 72) n (%)	Tofersen 100 mg (N = 104) n (%)
No. of participants with treatment-emergent event^a			
Any event	34 (94.4)	69 (95.8)	102 (98.1)
Related event ^b	2 (5.6)	28 (38.9)	63 (60.6)
Events related to lumbar puncture ^b	29 (80.6)	58 (80.6)	84 (80.8)
Events with fatal outcome	0	1 (1.4)	14 (13.5)
Events leading to drug discontinuation	0	4 (5.6)	18 (17.3)
Serious event	5 (13.9)	13 (18.1)	38 (36.5)
No. of participants with SAEs of note^c	0	4 (5.6)	7 (6.7)
Intracranial pressure increased	0	0	1 (1.0)
Myelitis/myelitis transverse	0	2 (2.8)	2 (2.0)
Lumbar radiculopathy	0	1 (1.4)	1 (1.0)
Meningitis aseptic/chemical	0	1 (1.4)	2 (2.0)
Nervous system disorder	0	0	1 (1.0)
Papilloedema	0	0	1 (1.0)

OLE = open-label extension; SAE = serious adverse event.

^aA Participant can appear in more than one category; ^bRelated as assessed by the investigator; ^cA participant is counted only once in each preferred term (MedDRA version 24.0); ^dan event in a placebo participant during VALOR is only counted once; an event in a tofersen participant during VALOR is counted in both the "VALOR/tofersen 100 mg" column, and again in the "VALOR and OLE Integrated" column.

Evidence of Biologic Effect Precedes Evidence of Clinical Benefit



Many thanks!



Thank you to the **study participants** and their **caregivers and families**, the VALOR and OLE Steering Committee, investigators and site staff, and the entire community, without whom these important studies could not have been conducted.



Presentation 48

Steering Committee

• Timothy Miller • Merit Cudkowicz • Angela Genge • Pamela Shaw • Gen Sobue

Principal Investigators

• Agessandro Abrahao • Ammar Al Chalabi • Jinsy Andrews • Ximena Arcila-Londono • Suma Babu • Michael Benatar • Robert Bucelli • Adriano Chio • Senda Ajroud-Driss • Angela Genge • Jonathan Glass • Ira Goodman • Daisuke Ito • Wendy Johnston • Merete Karlsborg • Jonathan Katz • Lawrence Korngut • Rebecca Kuenzler • Shafeeq Ladha • Eduardo Locatelli • Albert Ludolph • Nicholas Maragakis • Deborah Mason • Christopher McDermott • Theodore Mobach • Hideki Mochizuki • Seiichi Nagano • Daniel Newman • Nicholas Olney • Bjorn Oskarsson • Gary Pattee • Erik Piore • Colin Quinn • John Ravits • François Salachas • Christopher Shaw • Eric Sorenson • Hiroshi Takashima • Tatsushi Toda • Randall Trudell • Philip Van Damme • Lorne Zinman